{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:23:15Z","timestamp":1761826995901,"version":"build-2065373602"},"reference-count":53,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["ARCPGA2021120004244"],"award-info":[{"award-number":["ARCPGA2021120004244"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Waldenstr\u00f6m's macroglobulinemia (WM) is a rare, indolent lymphoproliferative disorder, genetically characterized by the presence of the\n                    <jats:italic>L265P<\/jats:italic>\n                    mutation in the\n                    <jats:italic>MYD88<\/jats:italic>\n                    gene in almost all cases, resulting in constitutive activation of NF\u2010kappa B (NF\u2010\u03baB). Despite its slow progression, WM remains incurable due to the lack of specific treatments. The efficacy of therapies capable of reactivating the antitumor response of T\u2010cells is well documented in various solid tumors. Apart from Hodgkin's lymphoma, these therapies have very mixed effects on B\u2010cell lymphomas, especially those with NF\u2010\u03baB activation. Here, we used the published\n                    <jats:italic>Myd88<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>L252P<\/jats:italic>\n                    <\/jats:sup>\n                    mouse model, which develops a WM\u2010like disease close to human WM. By focusing on T\u2010cell exhaustion and regulatory T\u2010cell expansion, we show how T\u2010cells located near WM\u2010like tumors in mice are disrupted, while\n                    <jats:italic>Myd88<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>L252P<\/jats:italic>\n                    <\/jats:sup>\n                    tumor B\u2010cells adopt an immunoregulatory phenotype evoking regulatory B\u2010cells. We also demonstrate, for the first time in the context of WM, the dual effect of Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK), able to decrease B\u2010cell activation and expansion and to partially reverse T\u2010cell depletion in\n                    <jats:italic>Myd88<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>L252P<\/jats:italic>\n                    <\/jats:sup>\n                    mice. With Ibrutinib as an example, this work provides new perspectives for the development of therapeutic combinations targeting tumor B\u2010cells while reactivating antitumor T\u2010cells.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70231","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:34:08Z","timestamp":1761820448000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uncovering regulatory B\u2010cell features associated with regulatory T\u2010cell expansion and global T\u2010cell exhaustion in Waldenstr\u00f6m macroglobulinemia\n                    <i>Myd88<\/i>\n                    <sup>\n                      <i>L252P<\/i>\n                    <\/sup>\n                    \u2010like lymphoplasmacytic lymphomas"],"prefix":"10.1002","volume":"9","author":[{"given":"Quentin","family":"Lemasson","sequence":"first","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Tabaud","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oph\u00e9lie","family":"T\u00e9teau","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien","family":"Carle","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Chabaud","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Feuillard","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"},{"name":"Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Faumont","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-980X","authenticated-orcid":false,"given":"Christelle","family":"Vincent\u2010Fabert","sequence":"additional","affiliation":[{"name":"UMR CNRS7276, Inserm1262 University of Limoges: Contr\u00f4le de la R\u00e9ponse Immune B et des Lymphoprolif\u00e9rations, Team 1, 2MB2C: Molecular Mechanisms of B Cell Cancerogenesis Limoges France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cyto.b.21995","article-title":"Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenstr\u00f6m macroglobulinemia","volume":"102","author":"Gayet M","year":"2021","journal-title":"Cytometry Part B Clin Cytometry"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m's macroglobulinemia","volume":"98","author":"Nguyen\u2010Khac F","year":"2013","journal-title":"Haematologica"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon SP","year":"2012","journal-title":"N Engl J Med"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard N","year":"2013","journal-title":"Leukemia"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/leu.2013.36","article-title":"How to manage Waldenstrom's macroglobulinemia","volume":"27","author":"Buske C","year":"2013","journal-title":"Leukemia"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"123","author":"Treon SP","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.15202","article-title":"How we manage patients with Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Simon L","year":"2018","journal-title":"Br J Haematol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","article-title":"B\u2010cell\u2010specific conditional expression of Myd88\n                  \n                     p.L252P\n                   leads to the development of diffuse large B\u2010cell lymphoma in mice","volume":"127","author":"Knittel G","year":"2016","journal-title":"Blood"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2019000588","article-title":"Human MYD88\n                  L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells","volume":"3","author":"Sewastianik T","year":"2019","journal-title":"Blood Adv"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.602868","article-title":"B\u2010cell\u2010specific Myd88 L252P expression causes a premalignant gammopathy resembling IgM MGUS","volume":"11","author":"Schmidt K","year":"2020","journal-title":"Front Immunol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641692","article-title":"Continuous MYD88 activation is associated with expansion and then transformation of IgM differentiating plasma cells","volume":"12","author":"Ouk C","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000726","article-title":"The EHA research roadmap: malignant lymphoid diseases","volume":"6","author":"Dreyling M","year":"2022","journal-title":"HemaSphere"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2011.12.031","article-title":"Immune surveillance and therapy of lymphomas driven by Epstein\u2010Barr virus protein LMP1 in a mouse model","volume":"148","author":"Zhang B","year":"2012","journal-title":"Cell"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-019-0228-y","article-title":"Inflamed phenotype of splenic marginal zone B\u2010cell lymphomas with expression of PD\u2010L1 by intratumoral monocytes\/macrophages and dendritic cells","volume":"16","author":"Vincent\u2010Fabert C","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-019-0391-x","article-title":"Pre\u2010clinical blocking of PD\u2010L1 molecule, which expression is down regulated by NF\u2010\u03baB, JAK1\/JAK2 and BTK inhibitors, induces regression of activated B\u2010cell lymphoma","volume":"17","author":"Vincent\u2010Fabert C","year":"2019","journal-title":"Cell Commun Signaling"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41423-018-0197-6","article-title":"Reproducing indolent B\u2010cell lymphoma transformation with T\u2010cell immunosuppression in LMP1\/CD40\u2010expressing mice","volume":"16","author":"Vincent\u2010Fabert C","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn G","year":"2005","journal-title":"J Clin Invest"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.4049\/jimmunol.178.7.4051","article-title":"Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3\/CD28\u2010costimulated autologous and allogeneic CD8+CD25\u2010 and CD4+CD25\u2010 T cells","volume":"178","author":"Hilchey SP","year":"2007","journal-title":"J Immunol"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL\u201012 upregulates TIM\u20103 expression and induces T cell exhaustion in patients with follicular B cell non\u2010Hodgkin lymphoma","volume":"122","author":"Yang Z\u2010Z","year":"2012","journal-title":"J Clin Invest"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T\u2010cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches JC","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma M","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B\u2010cell lymphoma","volume":"126","author":"Kiyasu J","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41419-021-04293-4","article-title":"Gut\u2010derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD\u2010L1 checkpoint blockade via TLR4\/MyD88\/AKT\/NF\u2010\u03baB pathway in pancreatic cancer","volume":"12","author":"Yin H","year":"2021","journal-title":"Cell Death Dis"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4334.4334","article-title":"Interactions between PD\u20101 and PD\u2010L1 and PD\u2010L2 promote malignant B\u2010cell growth in Waldenstrom macroglobulinemia","volume":"122","author":"Grote DM","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/bloodadvances.2018021113","article-title":"Soluble PD\u20101 ligands regulate T\u2010cell function in Waldenstrom macroglobulinemia","volume":"2","author":"Jalali S","year":"2018","journal-title":"Blood Adv"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","article-title":"Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation, and MyD88\u2010mutant progenitors precede Waldenstrom macroglobulinemia","volume":"2","author":"Kaushal A","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12967-022-03798-6","article-title":"Single\u2010cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstr\u00f6m macroglobulinemia","volume":"20","author":"Sun H","year":"2022","journal-title":"J Transl Med"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood-2010-01-264689","article-title":"Genomic deletion of the whole IgH 3\u2019 regulatory region (hs3a, hs1,2, hs3b, and hs4) dramatically affects class switch recombination and Ig secretion to all isotypes","volume":"116","author":"Vincent\u2010Fabert C","year":"2010","journal-title":"Blood"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cam4.1510","article-title":"Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients","volume":"7","author":"Chauzeix J","year":"2018","journal-title":"Cancer Med"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL\u201035\u2010producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen P","year":"2014","journal-title":"Nature"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2010immune set point","volume":"541","author":"Chen DS","year":"2017","journal-title":"Nature"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100351","article-title":"Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry","volume":"2","author":"Skordos I","year":"2021","journal-title":"STAR Protocols"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.immuni.2014.01.005","article-title":"Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection","volume":"40","author":"Crawford A","year":"2014","journal-title":"Immunity"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot JD","year":"2003","journal-title":"Nat Immunol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz SZ","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153733","article-title":"Human IL\u201010\u2013producing Th1 cells exhibit a molecular signature distinct from Tr1 cells in malaria","volume":"133","author":"Edwards CL","year":"2023","journal-title":"J Clin Invest"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109699","article-title":"Expression of Tim\u20103 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment","volume":"36","author":"Banerjee H","year":"2021","journal-title":"Cell Rep"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/ijc.34405","article-title":"Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenstr\u00f6m macroglobulinemia","volume":"152","author":"Cholujova D","year":"2023","journal-title":"Int J Cancer"},{"key":"e_1_2_10_40_1","first-page":"2615","article-title":"Targeting the immune microenvironment in Waldenstr\u00f6m macroglobulinemia via halting the CD40\/CD40\u2010ligand axis","volume":"141","author":"Sacco A","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD\u20101 and CTLA\u20104","volume":"18","author":"Qin S","year":"2019","journal-title":"Mol Cancer"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska A","year":"2015","journal-title":"Mol Oncol"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long M","year":"2017","journal-title":"J Clin Invest"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long\u2010term ibrutinib therapy reverses CD8+ T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"Parry HM","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first\u2010line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman IG","year":"2020","journal-title":"Leuk Res"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation\u2010induced senescence","volume":"19","author":"Davis JE","year":"2021","journal-title":"J Transl Med"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.962552","article-title":"Effects of ibrutinib on T\u2010cell immunity in patients with chronic lymphocytic leukemia","volume":"13","author":"Liu Y","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1\u2010selective pressure in T lymphocytes","volume":"122","author":"Dubovsky JA","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081338","article-title":"Ibrutinib in the treatment of solid tumors: current state of knowledge and future directions","volume":"11","author":"Szklener K","year":"2022","journal-title":"Cells"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166881","article-title":"Evolving perspectives regarding the role of the PD\u20101\/PD\u2010L1 pathway in gastric cancer immunotherapy","volume":"1870","author":"Yu X","year":"2024","journal-title":"Biochim Biophys Acta"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12876-022-02511-7","article-title":"Efficacy and safety of anti\u2010PD\u20101\/PD\u2010L1 therapy in the treatment of advanced colorectal cancer: a meta\u2010analysis","volume":"22","author":"Li Y","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","article-title":"Targeting PD\u20101\/PD\u2010L1 in cancer immunotherapy: an effective strategy for treatment of triple\u2010negative breast cancer (TNBC) patients","volume":"10","author":"Kumar S","year":"2023","journal-title":"Genes Dis"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070915","article-title":"Targeting the immune microenvironment in lymphomas of B\u2010cell origin: from biology to clinical application","volume":"11","author":"Mulder TA","year":"2019","journal-title":"Cancers"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.4049\/jimmunol.1801420","article-title":"EBV latency III\u2010transformed B cells are Inducers of conventional and unconventional regulatory T cells in a PD\u2010L1\u2010dependent manner","volume":"203","author":"Auclair H","year":"2019","journal-title":"J Immunol"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:16:06Z","timestamp":1761826566000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/hem3.70231"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70231","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"type":"print","value":"2572-9241"},{"type":"electronic","value":"2572-9241"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70231"}}